

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Director or senior manager giving disclosure

Ful	na	ame	e(s):	
Nex		- 4	المغم ما	

Name of listed issuer: Name of related body corporate (if applicable):

Position held in listed issuer:

Rua	Bioscience Limited (Rua)
15-A	Apr-21
8-Ap	

Manu Caddie
Rua Biosicence Limited
Kaihautu - Head of Innovation and
Regulation of Rua

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Ordinary shares in Rua
Nature of the affected relevant interest(s):	Manu is a director and 50% shareholder of New Zealand Nutraceuticals Limited (NZNL). NZNL is a limited partner of Hikurangi Bioactives Limited Partnership (HBLP) with a 40% economic interest in HBLP. HBLP is the registered holder and beneficial owner of 22,578,706 (before the transaction) and 22,384,130 (after the transaction) ordinary shares in Rua.
For that relevant interest-	
Number held in class before acquisition or disposal:	9,031,482
Number held in class after acquisition or disposal:	8.953,652
Current registered holder(s):	HBLP
Registered holder(s) once transfers are registered:	HBLP

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:

N/A			
N/A			

Details of affected derivative-

he notional value of the derivative (if any) or the notional amount of underlying financial roducts (if any):	
statement as to whether the derivative is cash settled or physically settled:	
<i>l</i> aturity date of the derivative (if any):	
xpiry date of the derivative(if any):	
he price specified in the terms of the derivative (if any):	
any other details needed to understand how the amount of the consideration payable inder the derivative or the value of the derivative is affected by the value of the underlyin mancial products:	3
For that derivative,-	
Parties to the derivative:	
f the director or senior manager is not a party to the derivative, the nature of the relevant nterest in the derivative:	

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

N/A		
N/A		
N/A N/A N/A N/A		
N/A		
N/A		

N/A		
N/A		

-		
2		
2		

Details of transactions requiring disclosure-

Date of transaction:	
Nature of transaction:	

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

Number of financial products to which the transaction related:

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):

Summary of other relevant interests after acquisition or disposal:

Class of c	uoted	financial	products:

Nature of relevant interest:

For that relevant interest,-

Number held in class:

Current registered holder(s):

For a derivative relevant interest,-



Details of derivative,-

Type of derivative:

The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative relevant interest,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer.

(a) 8 April 2021
(b) 9 April 2021
On market sale
Unknown
(a) NZ\$6724.32 being 40% of

proceeds of HBLP's sale of 41,002 shares for \$16,810.82 (before fees) (b) NZ\$24,727.80 being 40% of proceeds of HBLP's sale of 153,574 shares for \$61,819.52 (before fees)

(a) 16,400 (being 40% of 41,002) (b) 61,429 (being 40% of 153,574)

No	
N/A	
N/A	


Options that are convertible to ordinary shares in Rua under Rua's employee share option plan

Entitlement to become legal and beneficial owner subject to the meeting of vesting and other terms and conditions under Rua's employee share option plan

55,000 options potentially convertible to 283,072 ordinary shares N/A

N/A

N/A		
N/A		
N/A		



Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:

15/04/21